文献速递关节外科骨质疏松与代谢性骨病

含钴铬全髋关节置换假体与全因死亡、心脏结局、癌症及神经退行性疾病风险:国家关节登记分析

The risk of all-cause mortality, heart outcomes, cancer, and neurodegenerative disorders with cobalt-chrome-containing total hip arthroplasty implants : an analysis of the National Joint Registry.
PubMed 文献 · Bone Joint J · 2022-01-01

基于国家关节登记库374359例初次全髋关节置换术(随访至14.5年)的关联分析显示,含钴铬(CoCr)假体与全因死亡、心脏结局、癌症及神经退行性疾病风险升高无关;含CoCr组158677例(42.4%),发生死亡47963例、心脏结局27332例、癌症35720例、神经退行性疾病22025例。

要点

  • 含CoCr全髋假体未增加全因死亡、心脏结局、癌症及神经退行性疾病风险。
  • 研究基于国家关节登记库374359例初次全髋置换,随访至14.5年。
  • 含CoCr假体者158677例(42.4%),各结局发生率未见升高证据。

核心结论

  • 含CoCr的全髋关节置换术未增加全因死亡风险,也未增加有临床意义的心脏结局、癌症或神经退行性疾病风险,随访至植入后第二个十年。

研究设计与样本

  • 基于国家关节登记库与NHS英格兰医院住院记录链接的分析,纳入374359例初次全髋关节置换术,随访至14.5年。

主要发现

  • 含CoCr假体者158677例(42.4%),共发生死亡47963例、心脏结局27332例、癌症35720例、神经退行性疾病22025例。
  • 含CoCr假体患者与上述任一结局发生率升高均无关联证据。

关键数值与推荐

  • 排除双侧全髋置换、膝关节置换、非骨关节炎指征、年龄低于55岁及全髋置换前已诊断任一关注结局者。
  • 假体按含CoCr或不含CoCr分组,分析假体构建与全因死亡及新发心脏衰竭、癌症、神经退行性疾病风险的关联。

临床怎么用

  • 原文结论认为含CoCr假体的使用与显著不良全身效应无关,可帮助安抚临床医生及全球日益增多的初次全髋置换患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: A recent report from France suggested an association between the use of cobalt-chrome (CoCr) femoral heads in total hip arthroplasties (THAs) and an increased risk of dilated cardiomyopathy and heart failure. CoCr is a commonly used material in orthopaedic implants. If the reported association is causal, the consequences would be significant given the millions of joint arthroplasties and other orthopaedic procedures in which CoCr is used annually. We examined whether CoCr-containing THAs were associated with an increased risk of all-cause mortality, heart outcomes, cancer, and neurodegenerative disorders in a large national database. METHODS: Data from the National Joint Registry was linked to NHS English hospital inpatient episodes for 374,359 primary THAs with up to 14.5 years' follow-up. We excluded any patients with bilateral THAs, knee arthroplasties, indications other than osteoarthritis, aged under 55 years, and diagnosis of one or more outcome of interest before THA. Implants were grouped as either containing CoCr or not containing CoCr. The association between implant construct and the risk of all-cause mortality and incident heart failure, cancer, and neurodegenerative disorders was examined. RESULTS: There were 158,677 individuals (42.4%) with an implant containing CoCr. There were 47,963 deaths, 27,332 heart outcomes, 35,720 cancers, and 22,025 neurodegenerative disorders. There was no evidence of an association between patients with CoCr implants and higher rates of any of the outcomes. CONCLUSION: CoCr-containing THAs did not have an increased risk of all-cause mortality, or clinically meaningful heart outcomes, cancer, or neurodegenerative disorders into the second decade post-implantation. Our findings will help reassure clinicians and the increasing number of patients receiving primary THA worldwide that the use of CoCr-containing implants is not associated with significant adverse systemic effects. Cite this article: Bone Joint J 2022;104-B(3):359-367.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Deere K, Matharu GS, Ben-Shlomo Y, et al. The risk of all-cause mortality, heart outcomes, cancer, and neurodegenerative disorders with cobalt-chrome-containing total hip arthroplasty implants : an analysis of the National Joint Registry. Bone Joint J. 2022. PMID: 35227088. doi:10.1302/0301-620X.104B3.BJJ-2021-0397.R1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。